1. Inhibition of 5-lipoxygenase alleviates graft-versus-host disease.
- Author
-
Rezende BM, Athayde RM, Gonçalves WA, Resende CB, Teles de Tolêdo Bernardes P, Perez DA, Esper L, Reis AC, Rachid MA, Castor MGME, Cunha TM, Machado FS, Teixeira MM, and Pinho V
- Subjects
- Animals, Arachidonate 5-Lipoxygenase genetics, Benzopyrans pharmacology, Carboxylic Acids pharmacology, Cell Transplantation adverse effects, Chemokines metabolism, Cytokines metabolism, Graft vs Host Disease drug therapy, Graft vs Host Disease etiology, Hydroxyurea analogs & derivatives, Hydroxyurea pharmacology, Leukocytes cytology, Leukocytes enzymology, Leukocytes metabolism, Leukotriene Antagonists pharmacology, Leukotriene B4 antagonists & inhibitors, Lipoxygenase Inhibitors pharmacology, Mice, Inbred BALB C, Mice, Inbred C57BL, Microscopy, Confocal, Transplantation, Homologous, Arachidonate 5-Lipoxygenase metabolism, Cell Transplantation methods, Graft vs Host Disease metabolism, Leukotriene B4 metabolism
- Abstract
Leukotriene B
4 (LTB4 ), a proinflammatory mediator produced by the enzyme 5-lipoxygenase (5-LO), is associated with the development of many inflammatory diseases. In this study, we evaluated the participation of the 5-LO/LTB4 axis in graft-versus-host disease (GVHD) pathogenesis by transplanting 5-LO-deficient leukocytes and investigated the effect of pharmacologic 5-LO inhibition by zileuton and LTB4 inhibition by CP-105,696. Mice that received allogeneic transplant showed an increase in nuclear 5-LO expression in splenocytes, indicating enzyme activation after GVHD. Mice receiving 5-LO-deficient cell transplant or zileuton treatment had prolonged survival, reduced GVHD clinical scores, reduced intestinal and liver injury, and decreased levels of serum and hepatic LTB4 These results were associated with inhibition of leukocyte recruitment and decreased production of cytokines and chemokines. Treatment with CP-105,696 achieved similar effects. The chimerism or the beneficial graft-versus-leukemia response remained unaffected. Our data provide evidence that the 5-LO/LTB4 axis orchestrates GVHD development and suggest it could be a target for the development of novel therapeutic strategies for GVHD treatment., (© 2017 Rezende et al.)- Published
- 2017
- Full Text
- View/download PDF